In an era of persistent medical misinformation, addressing vaccine hesitancy has become a critical challenge for health care professionals.

Investigators said that targeted education and interventions are key to the long term success of community pharmacy immunization programs.

Antonio Ciaccia, President of 3 Axis Advisors, led a discussion on pharmacy benefit manager reform and how the inability to pass legislation has led to increased financial hardships in community pharmacy.

Jean-Venable Goode, BSPharm, PharmD, and Jeff Goad, PharmD, MPH, presented on the most notable vaccine updates from the past year and how they impact pharmacy practice.

Lydia Newsom, PharmD, discusses injection techniques, managing side effects, and the importance of collaboration between the healthcare team.

As information changed rapidly, pharmacists quickly adapted their strategies by leveraging social media for updates to patients.

Tom DePietro, PharmD, owner of DePietro's Pharmacy, highlights the deep community connections that enabled the pharmacy to respond effectively to the pandemic.

Fitusiran (Qfitlia) is approved for patients 12 years and older with or without factor VIII or IX inhibitors.

Currently, there is no vaccine to prevent chlamydia, but treatment includes regimens of antibiotics, including doxycycline, azithromycin, and levofloxacin.

Lauren Angelo, PharmD, MBA, discussed current vaccination sentiments across the country and how misinformation has contributed to declining rates among US patients.

Lucas Berenbrok, PharmD, MS, discussed pharmacy deserts and how closures around the US have the potential to impact public health.

Nicole Cieri-Hutcherson, PharmD, BCPS, MSCP, FCCP, clinical associate professor at University at Buffalo, discusses how pharmacists can implement an injectable contraception program.

Denosumab-bnht (Conexxence, Bomyntra) became the third biosimilar in 2025 to be approved for denosumab (Prolia, Xgeva).

Xyngari resulted in significant improvements in IGA treatment success, inflammatory lesion count, and non-inflammatory lesion count compared to placebo.

A conversation with Rob Frankil, RPh, executive director of the Philadelphia Association of Retail Druggists.

The decision makes the therapy the first oral antibiotic treatment approved for uUTIs in over 20 years.

Haley Pals, PharmD, BCPP, and Thomas Franko, PharmD, discussed the best approaches in the use of buprenorphine for treating patients with SUD.

Chichi Ilonzo Momah, PharmD, discussed what pharmacists can be doing to address vaccine hesitancy and the barriers impeding under-resourced communities.

Jade Ranger, co-owner and pharmacist of the Prescription Shoppe, discusses how her pharmacy put patients first during the COVID-19 pandemic.

The decision makes the RNAi therapeutic the only therapy approved by the FDA to treat ATTR-CM and hATTR-PN.

Heather Johnson, PharmD, BCACP, CTTS, and Heather Roth, BSPharm, RPh, discuss medications and devices used for improving cardiovascular health among patients with or without diabetes.

National Adverse Drug Event Awareness Day occurs annually on March 24 to raise awareness about minimizing the risk of adverse events caused by medications.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discusses the various errors patients experience when using CGM devices.

Stefanie Ferreri, PharmD, BCACP, FAPhA, discusses literature exploring OTC drugs, supplements, and devices used for non-prescription or self-care purposes.

Heather Johnson, PharmD, BCACP, CTTS, and Heather Roth, BSPharm, RPh, compare patients’ diabetes outcomes in clinical and community pharmacy settings.